Tasigna (nilotinib) — United Healthcare
Gastrointestinal Stromal Tumor (GIST)
Preferred products
- Gleevec (imatinib)
- Sutent (sunitinib)
- Stivarga (regorafenib)
- Qinlock (ripretinib)
Initial criteria
- Diagnosis of progressive gastrointestinal stromal tumor (GIST)
- AND
- History of failure, contraindication, or intolerance to all of the following:
- Gleevec (imatinib)
- Sutent (sunitinib)
- Stivarga (regorafenib)
- Qinlock (ripretinib)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Tasigna therapy
Approval duration
12 months